Correvio Pharma Corp (NASDAQ: CORV)( TSX: CORV), a specialty pharmaceutical company focused on commercialising hospital drugs, announced yesterday its financial results for its first quarter ended 31 March 2019.
The company reported a net loss of USD9m for the three months ended 31March 2019, compared to a net loss of USD8.5m in the year-ago period.
The firm posted revenue for the three months ended 31 March 2019 at USD7.3m compared to revenue of USD6.5m in the year-ago period.
Mark HN Corrigan, MD, CEO of Correvio, said, 2019 is off to a strong start with first quarter revenues up 16% year-over-year in local currencies. Our first quarter revenues from Xydalba and Zevtera doubled year-over-year. Looking ahead, we remain on track to resubmit the New Drug Application seeking approval in the US for BrinavessTM as a new treatment for adult patients with recent onset atrial fibrillation during the second quarter of 2019.'
Bruker Corporation to acquire ELITechGroup for EUR870m, strengthening MDx portfolio
Perrigo announces quarterly dividend increase
Bruker expands Preclinical Imaging Portfolio with acquisition of Spectral Instruments Imaging
Fusion Antibodies announces receipt of follow-on project and provides R&D update
Alvotech reports positive results for AVT03, potential biosimilar to Prolia and Xgeva
Biosenic finalises agreement with Phebra for oral arsenic troxide development